genetically modified T cells #1138

Genetically modified T cells #1138 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD30 (TNFRSF8), a cell surface receptor highly expressed in Hodgkin lymphoma and specific subtypes of cutaneous T-cell lymphoma. Developed by the University of Cologne, this therapy employs a second-generation CAR construct that includes a single-chain variable fragment (scFv) derived from the anti-CD30 antibody HRS3. To improve persistence and minimize off-target interactions, the construct utilizes a human IgG1 CH2CH3 hinge/spacer region modified with specific point mutations (PELLGGP to PPVA-GP) that eliminate binding to Fc-gamma receptors (FcγR). The intracellular signaling architecture typically incorporates the CD28 co-stimulatory domain and the CD3-zeta activation domain. Upon binding to CD30 on target cells, the engineered T cells undergo activation and proliferation, leading to the directed cytolysis of CD30-positive malignant cells. The therapy was primarily investigated in clinical trials for patients with relapsed or refractory primary cutaneous CD30+ large T-cell lymphoma or transformed CD30+ mycosis fungoides, administered through both systemic and topical routes.

Other names

anti-CD30 CAR-T cells #1138T cells #1138engineered T cells #1138HRS3-scFv CAR-T cellsHRS-3-scFv CAR-T cellsHRS 3-scFv CAR-T cells